Physician profile
Eugene Zeltser
NPI 1215948617
$990.26
in general payments reported to CMS, 2019-2025
15 companies · $35.07 in 2025
The $35.07 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $55.70 · 2021: $67.34 · 2022: $136 · 2023: $287 · 2024: $125 · 2025: $35.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $175.53 | 2019-2024 | Farxiga |
| Amgen INC. | $166.09 | 2019-2023 | Tavneos |
| Mallinckrodt Hospital Products INC. | $156.62 | 2021-2023 | Acthar |
| Fidia Pharma USA INC. | $122.24 | 2022 | |
| Vifor Pharma, INC. | $94.72 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $69.09 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $41.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.72 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $27.33 | 2019 | |
| Opko Pharmaceuticals, LLC | $27.24 | 2019-2020 | |
| Lilly USA, LLC | $16.53 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $15.55 | 2019 | |
| Horizon Therapeutics Plc | $14.91 | 2019 | |
| Akebia Therapeutics INC | $13.24 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Zeltser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.